Takeda exits cell therapy research
Takeda will seek an external partner to leverage its cell therapy platform technologies
Takeda will seek an external partner to leverage its cell therapy platform technologies
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
The new site enables end-to-end production of viral vector gene therapies
Subscribe To Our Newsletter & Stay Updated